Highlights & Sidelights From House Medicare Rx Benefit Debate
For future debate: Pharmaceutical pricing, pharmacy issues and prescription drug savings accounts are topics likely to be taken up by House members following passage of the "Medicare Modernization and Prescription Drug Act of 2002" (HR 4954). Rep. Doug Bereuter (R-Neb.) remarked that "after extensive consultation, House leadership has promised a vote" on pricing issues. "One such vote could be on an implementable drug reimportation program of FDA-approved drugs for individual, wholesale or retail sales." HR 4954 sponsor Rep. Bill Thomas (R-Calif.) noted that "there are still some concerns" from retail pharmacy "that, as we move forward in Congress, we will address." Rep. Joe Barton (R-Texas) added: "I would like to, at some point in time, make in order an option for those that want to use a prescription drug savings account to have that option, and, hopefully, later this year we will get that"...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth